Livin, a novel member of the human inhibitors of apoptosis protein (IAP) family, plays an important role in tumor progression and occurrence by inhibiting cell apoptosis. It is selectively expressed in the most common human neoplasms and appears to be involved in tumor cell resistance to chemotherapeutic agents. To investigate its possibility as a therapeutic target for human malignancies, we established two genetically different stable tumor cell lines (LoVo and SPCA-1) and RNA interference (RNAi) technique was employed to downregulate Livin expression in two human tumor cell lines. The specific downregulation of Livin expression in tumor cell lines significantly inhibited in vitro cell proliferation and in vivo tumorigenicity. Furthermore, Livin knockdown led to cell arrest in the G 1 /G 0 phase of cell cycle, eventual apoptosis and chemosensitivity enhancement in tumor cells. All these results indicate that RNAi-mediated downregulation of Livin expression can lead to potent antitumor activity and chemosensitizing effects in human cancers.
Introduction
The inhibitors of apoptosis protein (IAPs) consist of a group of structurally related proteins with antiapoptotic properties, which have been shown to interact with specific cysteine proteases, or caspases, required for the cleavage of certain proteins involved in the disassembly of the cell during apoptosis. 1, 2 At present, eight human IAP members have been identified, including C-IAP1, C-IAP2, NAIP, Survivin, XIAP (X-linked IAP), Bruce, ILP-2 and Livin. 3 Livin is a novel member of the IAP family, which has two splicing variants that contain open reading frames of 298 and 280 amino acids. 4 The two splicing variants are designated the longer and shorter variants as Livin-a and Livin-b, respectively. Livin-a is a splice variant 18 amino acids longer in the BIR-RING linking region than the Livin-b splice variant. 5 Livin is undetectable in most normal differentiated tissues, but is expressed at high levels in a wide variety of human malignancies, such as colon cancer, gastric cancer, breast carcinoma, melanomas and lung cancer. [6] [7] [8] [9] It has been reported that Livin might be involved in the progression of tumors, and the high levels of this molecule are correlated with tumor progression and patient outcome. 10, 11 The overexpression of Livin renders malignant cells resistant to chemotherapy, so the inhibitors of Livin are considered as potential adjuncts to chemotherapy in the treatment of malignant cancers. [12] [13] [14] Others' reports also showed that antisense oligonucleotides or small interfering RNA (siRNA) targeting Livin gene could reduce its expression, decrease viability and colony formation, induce apoptosis and enhance chemosensitivity of tumor cells. 15, 16 Thus, we believe that Livin will become a potential molecular target for cancer therapy.
RNA interference (RNAi) is the process of sequencespecific posttranscriptional gene silencing in a wide range of organisms, initiated by dsRNA (double-stranded RNA) that is homologous in sequence to the targeting gene. 17 Rapid progress has been made in the use of RNAi, and, more specifically, siRNAs as a means of attenuating the expression of specific proteins both in vitro and in vivo enabling virtually any protein target to be inhibited by these sequence-specific, dsRNA molecules. [18] [19] [20] Specific gene silencing can be achieved in a variety of cell systems using chemically synthesized siRNA or DNA vectorbased small hairpin RNA (shRNA). 21 Although other groups have employed RNAi by using synthesized small RNA to downregulate Livin expression, but the effects were transient. 16 To achieve a stable supply of anticancer siRNA for therapeutic purposes, plasmid vectors with shRNA expression cassettes under the direction of CMV and RNA polymerase III promoters, such as U6 and H1, which were processed to form siRNAs, were employed to stably inhibit endogenous gene expression. 22 To explore the potential of Livin as a novel therapeutic target, in the current study, we designed three pairs of shRNA according to Livin sequence (GenBank NM_139317), and they showed obvious differences in silencing efficiency. Moreover, we also established human tumor cell lines (LoVo and SPCA-1) stably expressing shLivin and selected LoVo-L1 (or SPCA-1-L1) for further study, which displayed minimal levels of Livin expression. The downregulation of Livin expression by shRNA significantly inhibited cell proliferation in vitro and tumorigenicity in vivo, induced cell arrest in the G 1 /G 0 phase of cell cycle and led to a notable induction of cell apoptosis. Furthermore, knockdown of Livin significantly enhanced in vitro and in vivo chemosensitivity to 5-fluorouracil (5-FU). All these observations indicate that Livin may be a critical determinant for tumorigenesis and RNAi targeting Livin will be explored to become a novel therapeutic strategy to chemosensitize human tumor cells.
Materials and methods

Cell lines and cell culture
The human colorectal cancer cell line (LoVo) and human lung cancer cell line (SPCA-1) were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 2.05 mM of L-glutamine, 100 units ml À1 penicillin and 0.1 mg ml À1 streptomycin. The cell lines were maintained in a humidified 5% CO 2 /95% ambient air atmosphere at 37 1C.
Construction of Livin shRNA expression vectors
Three sequences in Livin cDNA (NM_139317) 473-491, 361-379 and 336-354 bp were chosen as our target sites using siRNA design software downloaded from internet (http://www.ambion.com). The shRNA designed toward a nonspecific (NS) sequence was used as control. BLAST search against EST libraries was performed to confirm that no other human gene was targeted. DNA template encoding DNA were designed as follows: 19-nt target sequence as sense strand followed by a 9-nt spacer and complementary antisense strand and a minimal poly(A) sequence (5 0 -TTATTTCCTAGAAAATAAAAGTAACCT AGACACACAACCAAAAAACATACGCCGGCGA-3 0 ) was used as a terminal sequence. The shRNAs were subcloned into pSilencer4.1-CMVneo (Ambion, Austin, TX, USA) with human CMV promoter between the BamHI and HindIII enzyme sites (Figure 1 ). The recombinant vectors (pS-L1, pS-L2, pS-L3 and pS-NS) was confirmed by the digestion analysis of restriction endonuclease, and all inserted sequences were verified by DNA sequencing.
Transfection of plasmids
A total of 1 Â 10 4 cells were seeded into each well of a sixwell cell culture plate (CoStar, Cambridge, MA, USA), respectively. When the cells reached approximately 30-50% confluence, cells were transfected with different vectors (pS-L1, pS-L2, pS-L3, pS-NS and pS-CMVneo) in opti-MEM with the transfection reagent LipofectAMINE Plus (Life Technologies, Grand Island, NY, USA) following the manufacturer's instructions. Stably transfected cell lines were selected with G418 (800 mg ml
À1
) 48 h later after transfection and individual clones were isolated and maintained with G418 (200 mg ml
). Names of stable transfectants were LoVo-L1 and SPCA-1-L1 (transfected with pS-L1), LoVo-L2 and SPCA-1-L2 (transfected with pS-L2), LoVo-L3 and SPCA-1-L3 (transfected with pS-L3), LoVo-NS and SPCA-1-NS (transfected with pS-control), and LoVo-CMVneo and SPCA-1-CMVneo (transfected with pS-CMVneo parental vector), respectively.
Reverse transcription-PCR analysis Total RNA was extracted by using Trizol reagent (Invitrogen) following the manufacture's instructions. In all, 2 mg of total RNA was reverse-transcribed into cDNA using M-MLV reverse transcriptase (Invitrogen) in the presence of random primers. The cDNA was used to 
Western blot analysis The untransfected or stably transfected cells (LoVo and SPCA-1) were harvested by suspension in lysis buffer (1 mM dithiothreitol, 0.125 mM EDTA, 5% glycerol, 1 mM phenylmethylsulfonylfluoride, 1 mg ml À1 leupeptin, 1 mg ml À1 pepstatin, 1 mg ml À1 aprotinin, 1% Triton X-100 in 12.5 mM Tris-HCl buffer, pH7.0) at 4 1C for 30 min. An equal volume of lysate was electrophoresed with SDSpolyacrylamide gel electrophoresis (12%). The separated proteins in the gel were transferred to the nitrocellulose membrane. The membranes were blocked with Trisbuffered saline plus 0.1% TTBS (Tween-20) containing 5% nonfat milk for 1 h, incubated with the appropriate primary antibodies (anti-Livin (Merck, Darmstadt, Germany); anti-b-actin (Sigma, St Louis, MO, USA) in TTBS containing 5% nonfat milk for 2 h, followed by incubation with HRP (horseradish peroxidase)-conjugated anti-mouse immunoglobulin antibodies (Sigma) for 1 h. Band density was measured by photoimage analysis using the Quantity one software (Bio-Rad, Hercules, CA, USA), and expressed as the percentage of density of the respective housekeeping b-actin. Cells that had the higher downregulation of Livin expression were collected and used for further assay.
In vitro cell proliferation assay Four kinds of LoVo or SPCA-1 cells (cells without transfection, cells transfected with pS-CMVneo, pS-NS or pS-L1 vector), at 2 Â 10 4 per well, were seeded into seven 96-well culture plates, with each plate having all four kinds of cells and each group consisted of 12 parallel wells. Absorption value of one of seven culture plates was determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) at 490 nm after 24 h cultivation. Then, absorption value of every culture plate was detected in the following 6 days. The proliferation curve of each group was plotted on the basis of absorption values. The inhibitory rates of cell proliferation were calculated according to the following formula: inhibitory rate ¼½1 À LoVoðor SPCA-1Þ À L1 A= LoVo ðor SPCA-1Þ AÂ100%:
All experiments were performed in triplicate and results were statistically analyzed.
In vitro colony formation assay Approximately 3.0 Â 10 2 cells (LoVo or SPCA-1) stably transfected with pS-L1, pS-NS or pS-CMVneo parental vector were plated in 10-cm culture dishes. After 18 days, cells were fixed with methanol and stained with 0.1% crystal violet. Visible colonies were manually counted. 
Flow cytometry for detection of apoptotic cells
An annexin V-fluorescein isothiocyanate kit (Oncogene, San Diego, CA, USA) was used to detect apoptosis. The untransfected or stably transfected cells were harvested, washed with ice-cold phosphate-buffered saline (PBS) twice and resuspended in binding buffer (10 mM of Hepes, pH 7.4, 150 mM of NaCl, 2.5 mM of CaCl 2 , 1 mM of MgCl 2 , 4% bovine serum albumin). Annexin V-fluorescein isothiocyanate (0.5 mg ml
À1
) and PI (0.6 mg ml À1 ) were then added to a 100-ml aliquot (4.0 Â 10 6 cells) of this cell suspension. After a 15-min incubation in the dark at room temperature, stained cells were immediately analyzed by EPICS-ELITE-ESP Flow Cytometry (Coulter Biosciences, Beckman Coulter, Hialeah, FL, USA). All of the samples were assayed in triplicate, and the cell apoptosis rate calculated as: apoptosis rate ¼ðapoptotic cell number= total cell numberÞÂ100%:
TdT-mediated dUTP nick end labeling assay The stably transfected LoVo and SPCA-1 cells were seeded in 100 mm culture plate in which coverslip was put previously to allow the seeded cells to grow up. Then, the cells were collected in days 1, 3, 5 and 7 and determined by TdT-mediated dUTP nick end labeling (TUNEL) apoptosis detection kit (Keygen Biotech Co. Ltd, Nanjing, China) to detect the incorporation of labeled nucleotides to DNA strand breaks. Briefly, the cells were washed with PBS and fixed in 40 mg ml À1 paraformaldehyde solution for 25 min and permeabilization was done with Silencing Livin gene expression2 mg ml À1 Triton X-100 at 4 1C for 5 min. The cells were then washed and labeled with TUNEL reaction mixture at 37 1C for 60 min. After washing with SSC (saline sodium citrate) buffer, 100 ml streptavidin-HRP was added and incubated for another about 5 min, then 100 ml DAB (3, 3 0 -diaminobenzidine tetrahydrochloride) working solution was added and incubated for 5-10 min. The negative control was set up with no TdT enzyme added in the staining process.
Immunohistochemistry of lung tumors
The sections of the lung tissues embedded in paraffin were stained using anti-mouse Livin antibody (Genetix, Boston, MA, USA) at 1:200 dilution overnight at 4 1C. After brief washing, all slides were stained and visualized with a Histofine SAB-PO(M) kit (Nichirei, Tokyo, Japan) according to the manufacturer's instructions. Stained cells in tumor regions obtained from 10 mice were quantified in each treatment group. In each group, the Livin-positive area was determined in 20 fields from 10 mice in a blinded fashion. TUNEL-positive tumor cells were detected using a TUNEL apoptosis detection kit according to the manufacturer's protocols.
Orthotopic mouse lung treatment model Eight-week-old female BALB/c nu/nu mice were purchased from animal experiment center of the Fourth Military Medical University and breeded under pathogenfree conditions. Animal experiments in this study were carried out in accordance with medicine institutional guidelines of the Fourth Military Medical University. Orthotopic implantation was performed as described previously. 23 Briefly, after total intravenous anesthesia with pentobarbital sodium (30 mg kg À1 ), a midline incision was made in the baenosome. A suspension of SPCA-1 cells (1.0 Â 10 6 ) in 50 ml of PBS containing 20% of growth factor-reduced Matrigel (Becton Dickinson, Barcelona, Spain) was injected into the upper left lobe of lung, and the wound was closed with surgical metal clips. The cell concentration was necessary to achieve consistent local tumor growth within a week of implantation. Mice were divided into four treatment groups (n ¼ 10). At days 7 and 14 post implantation, a low midline incision was performed, and the orthotopically implanted mice were intratumorally coinjected with pS-L1, pS-NS and pS-CMVneo plasmids (250 mg each). To facilitate delivery of the vectors in vivo, the liposome transfection reagent LipofectAMINE Plus was applied in the ratio as follows: vector (mg)/Lipo (vol)/OPTI (vol) ¼ 1 mg:3 ml:100 ml. After the final shRNA plasmid injection, all mice were killed and s.c. tumors were resected and fixed in 10% PBS. We then excised, measured and weighed the primary tumors. The tumors were paraffin embedded and immunohistochemical staining for Livin was performed. TUNEL staining was performed on 5 mm sections of the excised tumors according to the manufacturer's instructions. The number of apoptotic cells in five random high-power fields was counted and expressed as a percentage of total cells (apoptotic fraction). Survival tests were made using groups of mice (n ¼ 10) treated as above and monitored daily until all the mice died.
Chemosensitivity assay
In vitro, cell chemosensitivity to 5-FU (Sigma) was assessed by MTT analysis and apoptosis detection assay, stably transfected or untransfected LoVo or SPCA-1 cells (1.
À Þ Â100%. The cell apoptosis was evaluated as described. The tumor in vivo chemosensitivity to 5-FU was evaluated in the mouse model. SPCA-1 lung tumors were generated as above. When orthotopically implanted lung tumors reached the size of about 2.0 cm in diameter. After intratumor injection of various pS-L1, pS-NS or pS-CMVneo (250 mg) thrice every weekly, 5-FU (12.5 mg kg
À1
; twice weekly) or 0.1 ml PBS was intravenously injected via the tail veins. Tumor proliferation was evaluated by the average size of tumors and tumor size was calculated as already described. The tumor size was followed up weekly up to 10 weeks. Animal experiments in this study were carried out in accordance with Medicine Institutional Guidelines of the Fourth Military Medical University.
Statistical evaluations
Data were expressed as mean±s.e.m. Student's t-test was used to evaluate the difference between two groups. Statistical significance of differences in tumor weight was calculated by using the Mann-Whitney U-test. Survival curves were computed using the Kaplan-Meier method. Po0.05 was considered to be significant.
Results
Construction of shRNAs expressing vectors from pSilencer4.1-CMVneo
We constructed three vectors expressing shRNAs against Livin and one vector expressing nonspecific shRNA. Those corresponding plasmids were named pS-L1, pS-L2, pS-L3 and pS-NS, respectively (Figure 1 ). DNA sequencing confirmed all vectors were correct.
DNA vector-mediated RNAi downregulates Livin expression
To assess the role of the overexpression of Livin in tumor cells, we first established subclones via the transfection of DNA vector-based shRNA (pS-shLivin(L1, L2 or L3), pS-NS and pS-CMVneo) in LoVo and SPCA-1 cells. Stably transfected cells were collected for reverse transcription-PCR and western blotting detection. The levels of Livin mRNA and protein expression were efficiently decreased (by 51.4 and 60.8%, in LoVo-L1; by 66.1 and 73.2%, in SPCA-1-L1) but were not decreased in other stably transfected subclones (pS-L2, pS-L3, pS-NS or pSCMVneo; Figures 2 and 3 ). All the above meant that the plasmid pS-shLivin-1 (pS-L1) had a better interfering effect on Livin expression in tumor cells, and we chose LoVo-L1 and SPCA-1-L1 subclones for further study.
Livin downregulation inhibits in vitro cell proliferation and colony formation
To analyze phenotypical changes induced by Livin downregulation, we first investigated shRNA targeting Livin on the proliferation of LoVo and SPCA-1 cells in vitro. In this experiment, cellular proliferation was mornitored by MTT assay daily for 7 days. The cell proliferation curves showed that the LoVo-L1 and SPCA-1-L1 cell proliferation was significantly inhibited in a time-dependent manner, and the highest inhibitory rates were 59.8 ± 1.32 and 62.2 ± 2.46% (Po0.05) on day 7, but LoVo (or SPCA-1)-NS and LoVo (or SPCA-1)-CMVneo cells showed no significant inhibition of the proliferation (P40.05; Figure 4 ). In colony formation assay, as expected from the MTT assay, the numbers of colonies developed from LoVo-L1 or SPCA-1-L1 cells were obviously decreased ( Figure 5 ). These results were statistically significant with a P-value of o0.01 and 0.05, respectively (Student's t-test). All results suggested that Livin downregulation could lead to significant inhibition of tumor cells proliferation in vitro.
The effect of Livin siRNA on the cell cycle To reveal the mechanisms underlying the siRNAmediated growth inhibition and analyze cell-cycle distribution, we performed cell-cycle analysis of LoVo and SPCA-1 cells (stably transfected with pS-L1, pS-NS or pS-CMVneo parental vector) by flow cytometry. The population of cells in G 0 /G 1 phase was significantly increased in LoVo-L1 (54.8±3.24%) and SPCA-1-L1 (56.9 ± 3.74%) than that in the pS-NS or pS-CMVneo parental vector-transfected cells (LoVo: 42.8 ± 2.11 and 43.3±2.82%, Po0.05; SPCA-1: 48.4±3.88 and 46.7 ± 4.01%, Po0.05), while a marked increase in the sub-G 1 population was also detected in both pS-L1-transfected tumor cells (LoVo-L1: 13.6±1.0%, Po0.05; SPCA-1-L1: 12.9 ± 1.58%, Po0.05; Figure 6 ).
Increased cell apoptosis induced by RNAi targeting Livin
To further investigate the effect of Livin expression inhibition on apoptosis, we performed flow cytometry and TUNEL assay to detect cell apoptosis. Compared with parental vector-transfected cells, the apoptotic rates of LoVo-L1 and SPCA-1-L1 cells obviously increased to 14.1±0.4 and 13.5±0.6%, respectively (Po0.05), whereas there were no obvious differences in LoVo-NS or SPCA-1-NS cells (P40.05; Figure 7) . By TUNEL assay, a dark brown DAB signal indicating positive staining was observed in LoVo-L1 and SPCA-1-L1 cells, but not in LoVo-CMVneo (or LoVo-NS) and SPCA-1-CMVneo (or SPCA-1-NS) cells (Figure 8 ). All these results indicated that the RNAi-mediated Livin downregulation could lead to accelerated apoptosis of tumor cells.
Downregulation of Livin suppresses tumorigenesis in nude mice
Although we have observed the significant effects of Livin downregulation by RNAi in tumor cells in vitro, we do not know whether Livin RNAi would also inhibit the tumorigenicity of preestablished SPCA-1 orthotopic tumors in nude mice. SPCA-1 cells were inoculated intrapulmonarily in the upper left lobe of lung. On days 7 and 14 post implantation, the tumors were injected with plasmid constructs (pS-L1, pS-NS or pS-CMVneo). Then, Silencing Livin gene expression R Wang et al the mice were killed 2 weeks after the second dose of RNAi treatment, as was necessitated by the morbidity resulting from the tumors that had formed in control groups. First, we examined the situation of primary tumors and tumor metastasis. No metastasis was observed visually in mice treated with the pS-L1 plasmids, whereas mice treated with pS-NS, pS-CMVneo and mock presented with secondary tumors in addition to the primary tumor in the lung. Then, tumors were dissected and tumor size was monitored. Although pS-L1 treatments did not suppress tumor growth completely, the sizes of the tumor masses formed from pS-L1 treatment groups were significantly smaller than tumors from the control treatment groups (Figure 9a ). Western blot analysis for protein levels in tumor tissues confirmed that the tumors treated with pS-L1 had significantly reduced Livin protein levels by 54.6% compared with other control tumors ( Figure 9b ). Next, we performed immunohistochemical analysis on the harvested paraffin-embedded tumor tissues to determine the effects of Livin siRNA on the in vivo effects of SPCA-1 cells. Livin immunoreactivity was confirmed to be significantly reduced in tumors treated with pS-L1 but not in tumors treated with mock, pSCMVneo and pS-NS (Figure 9c) . To test the effect of Livin siRNA on the in vivo apoptosis, the paraffinembedded tumor sections from all treatment groups were stained for apoptotic markers using TUNEL staining analysis. This end labeling for apoptotic cells showed obvious differences among treatment groups. Tumor sections from mice treated with pS-L1 plasmids had a higher apoptotic fraction than those from control treatment groups (Figure 9d) . Followingly, we examined the survival of tumorbearing mice treated with mock, pS-CMVneo, pS-NS and pS-L1, respectively. The median survivals (in days) Figure 5 Colony formation assay. The pS-L1-transfected LoVo (or SPCA-1) cells showed much less colonies than the pS-CMVneo and pS-NStransfected LoVo (or SPCA-1) cells. These experiments were performed three times. *Po0.05. Figure 4 Cell proliferation detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The protracted cell growth curve and the results of the inhibitory rates of cell growth were applied to absorbance (A) at 490 nm. The proliferation of LoVo-L1 and SPCA-1-L1 cells was inhibited significantly in a time-dependent manner, and the highest inhibitory rates were 59.8 ± 1.32 and 62.2 ± 2.46%, respectively, (Po0.05) on day 7.
Silencing Livin gene expression R Wang et al were 51 in pS-L1 group, 28 in the PBS group, 32 in pS-CMVneo and 35 in pS-NS treatment group. Mice treated with pS-L1 lived significantly longer than all control groups (Figure 9e ; Po0.01). All these results indicated that RNAi-mediated knockdown of Livin exerted a strong in vivo antitumorigenic effect on tumor cells.
The effect of Livin downregulation on chemosensitivity to 5-FU in vitro and in vivo It has been reported that the overexpression of Livin is associated with the apoptosis-resistant phenotype of tumor cells, and Livin can confer resistance to some chemotherapeutic drugs. In this report, we want to investigate whether RNAi-mediated Livin inhibition The stably transfected tumor cells were transferred into 96-well trays, and exposed to 5-FU for a further 48 h. The IC 50 was determined at this time by MTT assay (data not shown). As shown in Figure 10a , Livin siRNA induced a significant decrease in the 5-FU IC 50 in two tumor cell lines. The survival index in LoVo-L1 and SPCA-1-L1 cells was significantly decreased with the addition of 5-FU (from 20 to 160 mg ml À1 ) relative to controls (Po0.05; Figure 10b ). We also observed that the apoptotic fraction of LoVo-L1 and SPCA-1-L1 cells significantly increased following 5-FU treatment (Figure 10c) . Next, we examined the possible effects of Livin siRNA on chemosensitivity to 5-FU in vivo, consistent with the in vitro chemosensitivity data, tumor inhibition of 5-FU in vivo was also significantly enhanced by RNAi targeting Livin. As shown in Figure 11a , the tumor growth in the pS-L1-treated mice was suppressed to a greater extent and in an extended period as compared with the mock-, pSCMVneo-and pS-NS-treated ones. At the end point of the chemosensitivity study, we monitored tumor size. The average tumor size was 463.3±172.0 mm 3 in pS-L1 þ 5-FU-treated mice much smaller than those in the control groups (754.2 ± 204.7 mm 3 in only 5-FU, 721.8 ± 188.36 mm 3 in pS-NS þ 5-FU and 704.1±177.6 mm 3 in pSCMVneo þ 5-FU-treated ones) (Po0.05; Figure 11b ). Thus, we could conclude that RNAi targeting Livin could synergistically enhance cytotoxicity of the chemotherapeutic agent 5-FU.
Discussion
The IAPs, a family of highly conserved cell apoptosis inhibitors, suppress apoptosis by binding and inhibiting upstream and downstream caspases. 24, 25 Livin, also called melanoma IAP or kidney IAP, is a novel member of human IAP family members. Previous reports have indicated that Livin is low expressed or not expressed in human normal tissues, but it is upregulated in a variety of human cancers. 26 Moreover, high levels of Livin expression contribute to tumor progression, a poor prognosis and correlate with more aggressive behaviors, such as decreased the response to chemotherapeutic agents and shortened survival time. 27 To explore the potential of Livin as a therapeutic target, we employed DNA vectorbased siRNA technique to downregulate its expression and analyzed its phenotypical changes in human tumor cells.
Livin gene, as a result of two alternatively spliced transcripts, can give rise to two different isoforms of the protein: Livin-a and Livin-b, the whole cDNA sequence of which is 897 and 843 bp, respectively. 28 The main difference between these two splicing variants lies only in the 54-bp domain deficient in exon 6 of Livin-b. Despite very close similarity of the two isoforms, they have different antiapoptotic properties. In recent studies, it has been reported that the specific knockdown of Livin-b inhibits the proliferation of HeLa cells, and silencing Livin sensitizes those cells to different proapoptotic stimuli such as UV irradiation, tumor-necrosis factor-a or etoposide. 29, 30 In the present study, we selected the upstream open reading frame owed by both Livin-a and Livin-b to design three siRNAs targeting Livin gene and successfully transfected them into two human tumor cell lines, LoVo and SPCA-1. Those stable transfectants showed significantly decreased levels of transcribed mRNA and protein. pS-L1 was efficient but pS-L2 and pS-L3 were inefficient. The above results suggested that DNA vector-based Livin-specific shRNA could specifically downregulate the expression of Livin in human tumor cell lines, and shRNA from different sites on the same target mRNA might be different in silencing efficiency. Silencing Livin gene expression R Wang et al Followingly, we examined the phenotypical changes of LoVo and SPCA-1 cells stably transfected with specific Livin siRNA. In this study, we observed that the downregulation of Livin expression induced cell arrest in the G 0 /G 1 phase of cell cycle, which resulted in significant cell proliferation and colony formation inhibition in vitro. We detected obvious cell apoptosis induction in the stably transfected tumor cells by flow cytometry (FCM) and TUNEL assay. Moreover, we also showed that the downregulation of Livin expression in tumor cell lines suppressed tumor growth in vivo in a mouse xenograft model using our vector-mediated siRNA strategy. Our experimental data were consistent with Wang et al. in terms of antitumor activity that Livin inhibition induced in LiBr or other human tumor cells. 31, 32 Thus, we have reasons to believe that Livin should be a potent therapeutic molecular target for inhibiting growth of human cancers.
The development of resistance of tumor cells to anticancer drugs is one of the critical issues for successful chemotherapy, whereas drug resistance is also an important cause of treatment failure and morality in human cancer patients. The overexpression of Livin has been reported in multidrug-resistant tumor cells. In (e) Survival analysis of mice treated with mock, pS-CMVneo, pS-NS or pS-L1. Survival days were determined from the day of SPCA-1 injection until the day of death. Survival curves were made by the Kaplan-Meier method, and statistical differences were evaluated by using the log-rank test. The differences between the treatment group and the two control groups are statistically significant, *Po0.01.
this study, we found that the downregulation of Livin expression enhanced the chemosensitivity to 5-FU not only in vitro but also in vivo. Crnkovic´-Mertens et al. 12 reported that targeted inhibition of Livin strongly sensitized NSCLC (non-small cell lung carcinoma) cells to different proapoptotic stimuli, such as the chemotherapeutic drug etoposide. Additionally, Sun et al. 13 reported that gene transfection of Livin isoforms into A549 cell line reduced sensitivity to chemotherapy. Our results were consistent with their studies. Thus, we think that it was not accidental that the levels of Livin expression would affect chemosensitivity of tumor cells. Although we only evaluated the chemosensitivity of Livin-inhibited LoVo and SPCA-1 cells to 5-FU in this report, we would select various human tumor cell lines and various chemotherapeutic agents to further evaluate the relationship between Livin expression and chemosensitivity in the following studies. As to the precise mechanism of how Livin downregulation enhances chemosensitivity, it remains to be further clarified, and, at present, it is mainly considered that the downregulation sensitizes cells to death induction via mitochondrial pathway or increases cell death induced by the death receptor pathway. 33, 34 Our results suggest that 5-FU chemotherapy could be more effective in combination with RNAi-mediated knockdown of Livin expression.
Taken together, we demonstrated that plasmid vectormediated RNAi targeting Livin could significantly suppress human cancer growth and enhance chemosensitivity to 5-FU both in vitro and in vivo. Thus, the therapeutic regimen with combined use of RNAi targeting Livin and chemotherapeutic agents may emerge as a potent and safe strategy for the treatment of human cancers. Further studies should focus on the delivery strategies that can direct vectors expressing Livin siRNA specifically into tumor cells with low toxicity and high efficiency. Silencing Livin gene expression R Wang et al
